Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
äŒæ¥ã³ãŒãGCTK
äŒç€ŸåGlucoTrack Inc
äžå Žæ¥Apr 09, 2013
æé«çµå¶è²¬ä»»è
ãCEOãGoode (Paul V)
åŸæ¥å¡æ°11
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Apr 09
æ¬ç€Ÿæåšå°301 Rt 17 North
éœåžRUTHERFORD
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·07070
é»è©±çªå·197286757878
ãŠã§ããµã€ãhttps://glucotrack.com/
äŒæ¥ã³ãŒãGCTK
äžå Žæ¥Apr 09, 2013
æé«çµå¶è²¬ä»»è
ãCEOãGoode (Paul V)